reports
Guerbet: Appointment of Mr. François Convenant as Senior Vice Presiden...
Guerbet: Appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Guerbet announces the appointment of Mr. François Convenant as Senior Vice President of Interventional Radiology and his entry into the Executive Committee Villepinte, December 19, 2025: GUERBET (FR0000032526 GBT), a global player in medical imaging, announces the appointment of François Convenant as Senior Vice President of Interventional Radiology.In this role, he joins the Guerbet Group's Executive Committee (COMEX). This appointment marks an...
GUERBET: Nomination de M. François Convenant en tant que Senior Vice-P...
GUERBET: Nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif Guerbet annonce la nomination de M. François Convenant en tant que Senior Vice-Président Radiologie Interventionnelle et son entrée au Comité Exécutif Villepinte, le 19 décembre 2025 : GUERBET (FR0000032526 GBT), acteur mondial de l’imagerie médicale, annonce la nomination de François Convenant au poste de Senior Vice-Président Radiologie Interventionnelle. À ce titre, il rejoint le Comité Exécutif (COMEX) du groupe Guerbet. Cette nomination mar...
LISI Group: 1 director
A director at LISI Group bought 1,000 shares at 50.197EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
Appointment of François Michel as Chief Executive Officer of the GTT G...
Appointment of François Michel as Chief Executive Officer of the GTT Group Appointment of François Michel as Chief Executive Officer of the GTT Group Paris, 15 December 2025 – The GTT Group announces the appointment of François Michel as Chief Executive Officer, effective 5 January 2026, thereby restoring a dissociated governance structure. This decision was taken unanimously by the Board of Directors of the Group at its meeting held on 13 December 2025. Following a demanding selection process, the Board of Directors selected François Michel for his managerial experience, his strong com...
Nomination de François Michel en qualité de Directeur général du group...
Nomination de François Michel en qualité de Directeur général du groupe GTT Nomination de François Michel en qualité de Directeur général du groupe GTT Paris, le 15 décembre 2025 – Le groupe GTT annonce la nomination de François Michel en qualité de Directeur général, à compter du 5 janvier 2026, et retrouve ainsi une gouvernance dissociée. Cette décision a été prise à l’unanimité par le Conseil d’administration du Groupe, réuni le 13 décembre 2025. À l’issue d’un processus de sélection exigeant, le Conseil d’administration a retenu la candidature de François Michel pour son expérience ...
- Maissa Keskes
- Stephane Houri
- Aurelien Sivignon
- Aurelien Sivignon
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
- Elias New
- Philip Hettich
GBT GUERBET SA
CDA COMPAGNIE DES ALPES SA
BOSS HUGO BOSS AG
A1XA4J CARBIOS SA
QDT QUADIENT SA
CAI CA IMMOBILIEN ANLAGEN AG
UBS UBM DEVELOPMENT AG
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
COPN COSMO PHARMACEUTICALS NV
M MED LIFE
WAVE WAVESTONE SA
LOUP SOCIETE L.D.C.
SHA SCHAEFFLER AG
- Aurelien Sivignon
- Aurelien Sivignon
- Christophe-Raphaël Ganet
- Christophe-Raphaël Ganet
GUERBET : Adjustment of 2025 financial targets.
GUERBET : Adjustment of 2025 financial targets. Adjustment of 2025 financial targets Villepinte, 2 December 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing a downward revision to its financial targets for full-year 2025. Following an inspection by the U.S. Food and Drug Administration (FDA) during the first half of the year, the Guerbet Group developed and initiated the implementation of a compliance plan at its Raleigh site in the United States. This plan has been reinforced over the past weeks in respo...
GUERBET : Ajustement des objectifs financiers 2025.
GUERBET : Ajustement des objectifs financiers 2025. Ajustement des objectifs financiers 2025 Villepinte, le 02 décembre 2025, 17h45 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, annonce une révision à la baisse de ses objectifs financiers pour l’exercice 2025. Faisant suite à une inspection de la Food and Drug Administration (FDA) au premier semestre, le Groupe Guerbet a défini et mis en place un plan de remise en conformité de son site situé à Raleigh, aux Etats-Unis. Ce plan a été renforcé ces dernières semaines en ré...
- Klaus Ringel
- Thomas Zlowodzki
- Klaus Ringel
- Thomas Zlowodzki
- Aurelien Sivignon
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.